The FY2025 (Dec) proxy of Merck & Co. names 12 peer companies for pay. Among Merck & Co. and these peers, CEO pay was the lowest of 7 and total shareholder return was 4th highest of 7.
7th highest of 7in Merck & Co. and its pay peers, FY2025 (Dec) by CEO pay:
$20.8M$32.8M
4th highest of 7in Merck & Co. and its pay peers, FY2025 (Dec) by total shareholder return:
$86$259
Pay peer group, FY2025 (Dec) proxy
| Johnson & Johnson | ||
| AbbVie | ||
| Gilead Sciences | ||
| Pfizer | ||
| Amgen | ||
| Bristol Myers Squibb | ||
| AstraZeneca | Not disclosed | Not disclosed |
| Eli Lilly | Not disclosed | Not disclosed |
| GlaxoSmithKline | Not disclosed | Not disclosed |
| Novartis | Not disclosed | Not disclosed |
| Roche Holding AG | Not disclosed | Not disclosed |
| Sanofi | Not disclosed | Not disclosed |
12 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.